Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) is a cancer driver gene, and 1.7–3% of NSCLC patients harbor HER2 mutations (5–7). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.